Why Sana Biotechnology, Inc.’s (SANA) Stock Is Down 6.69%
As of Wednesday, July 29, Sana Biotechnology, Inc.’s SANA share price has dipped by 6.69%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Commentary & Analysis
Why Sana Biotechnology, Inc.’s (SANA) Stock Is Up 6.29%
As of Monday, July 27, Sana Biotechnology, Inc.’s SANA share price has surged by 6.29%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Sana Biotechnology, Inc.’s (SANA) Stock Is Down 5.77%
As of Thursday, July 16, Sana Biotechnology, Inc.’s SANA share price has dipped by 5.77%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Sana Biotechnology, Inc.’s (SANA) Stock Is Down 5.34%
As of Friday, July 10, Sana Biotechnology, Inc.’s SANA share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Sana Biotechnology, Inc.’s (SANA) Stock Is Down 5.83%
As of Wednesday, July 08, Sana Biotechnology, Inc.’s SANA share price has dipped by 5.83%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | SANA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $938.7 | $252.6 | 44% |
|
| Shares Out (Mil) | 276.9 | 52.3 | 82% |
|
| Institutional Ownership | 88.5% | 92.1% | 56% |
|
| Float (Mil) | 191.5 | 40.2 | 73% |
|
| Beta | 2.18 | 0.95 | 94% |
|
| Avg Daily Volume (000s) | 2,480 | 455 | 85% |
|
| Price Change (52-week) |
(28.2%) | 52.9% | 26% |
|
| Growth | SANA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 3.1% | (9.9%) | 44% |
|
| EPS (5yr) | 46.5% | 16.0% | 91 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.6%) | (15.6%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.120) | ($0.580) | ($0.522) | |
| Month Ago EPS | ($0.120) | ($0.580) | ($0.522) | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.147) | ($0.580) | ($0.531) | |
| Year/Year Chg | (29.8%) | (39.8%) | (46.2%) | |
| Financials | SANA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($242) | ($43) | 6% |
|
| EPS (TTM) | ($0.920) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($133) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($12) | $5 | 29% |
|
| Long-Term Debt (Q1) (Mil) | $67 | $5 | 42% |
|
| Enterprise Value (Q1) (Mil) | $889 | $180 | 40% |
|
| Valuation | SANA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.11 | 2.56 | 85% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | SANA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (59.1%) | (49.8%) | 10% |
|
| ROE | (147.4%) | (55.5%) | 6% |
|
| Liabilities to Assets | 68.1% | 30.3% | 63% |
|
| F-Score | 1 | 3 | 1% |
|
Sana Biotechnology, Inc. did not pass any screens on 7/31/2026.
